MBC 11

Drug Profile

MBC 11

Alternative Names: Cytarabine/etidronic acid; Etidronic acid/cytarabine; MBC-11; MBC-11 -29

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator MBC Pharma
  • Developer MBC Pharma; Osteros Biomedica
  • Class Antihypercalcaemics; Antineoplastics; Arabinonucleosides; Bisphosphonates; Calcium regulators; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone metastases

Most Recent Events

  • 01 Dec 2015 Osteros Biomedica completes a phase I trial in Bone metastases in Russia (IV) (NCT02673060)
  • 27 Oct 2014 Phase-I clinical trials in Bone metastases in Russia (IV) (NCT02673060)
  • 19 Sep 2012 MBC 11, the lead candidate from MBC Pharma's cancer therapeutics research programme, licensed to Osteros Biomedica worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top